Paul Hudson appointed to boost Sanofi's growthNovartis' Paul Hudson has been appointed Sanofi's new chief executive to boost growth, FAZ said on Saturday (p22) and Handelsblatt on Tuesday (p46) (APMHE 63257).
Novartis' Tschudin will deal with pricing talks on ZolgensmaMarie-France Tschudin, who was appointed to succeed Paul Hudson, will have to deal with the pricing talks on gene therapy Zolgensma (onasemnogene abeparvovec) that are expected to be tough, Handelsblatt said on Tuesday (p46).
German pharma managers are the top earnersGerman pharma managers are the top earners among industrial sectors, according to a survey by job recruitment firm Stepstone, Die Welt said on Sunday (p42).
Stada buys GSK's consumer health brandsGerman generics manufacturer Stada will acquire a portfolio of five skin care brands and a paediatric cough medicine from GlaxoSmithKline, FAZ reported on Saturday (p21) (APMHE 63266).
J&J tippedJohnson & Johnson is among the 10 companies recommended to investors by Handelsblatt on Friday (p47).
Novo Nordisk to put an end to insulin injection for type 2 diabetes patientsNovo Nordisk, also recommended to shareholders by Handelsblatt on Friday (p49), is about to put an end to insulin injection for type 2 diabetes patients.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.